Study of quality markers of antiuric acid formula by grey relational analysis

Abstract

Gout has become a global problem, antiuric acid formula (AAF) is a clinical prescription highly effective in reducing uric acid levels. In order to find its quality control standards and contribute to the treatment of gout in the future, we adopted high-performance liquid chromatography and orbitrap liquid chromatography–mass spectrometry to establish fingerprints of 13 batches of AAF. The different batches of AAF were tested the activity of inhibit uric acid by the xanthine oxidase inhibition experiment. Grey relational analysis and bio-activity validation to assess the spectrum–effect relationship. Finally, we choose puerarin, calycosin-7-O-beta-d-glucoside and puerarin apioside as the AAF quality control component, and its average content is 6036.006 μg/g, 296.113 μg/g and 878.285 μg/g. As the quality control components of AAF, puerarin, calycosin-7-O-beta-d-glucoside and puerarin apioside can be of great significance for the treatment of gout and gout related research.

Mechanism of flavonoids in the treatment of gouty arthritis (Review)

“…Inhibiting NF-κB activation presents a valid strategy for improving gouty arthritis. Studies (79,80) have demonstrated that calycosin reduces knee joint swelling and neutrophil infiltration in a mouse model of gouty arthritis induced by MSU. Inflammatory markers such as IL-1β, IL-6, IL-10 and TNF-α showed notable decreases in peripheral blood mononuclear cells and THP-1 cells induced by 0.2 mg/ml MSU after a 24-h pre-treatment with calycosin.…”